• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • DeviceTalks Weekly
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates
Home » Conviction stands for ex-ArthroCare CEO Baker in $750m fraud case

Conviction stands for ex-ArthroCare CEO Baker in $750m fraud case

October 13, 2017 By Brad Perriello

Gavel, handcuffsA federal judge Texas this week upheld the conviction of former ArthroCare CEO Michael Baker on eight counts of wire fraud, rejecting his argument citing a recent U.S. Supreme Court case.

Baker and ex-ArthroCare CFO Michael Gluk were convicted in June 2014 on charges that they ran a scheme to generate false revenue numbers by dumping inventory, first with a distributor called DiscoCare and eventually via free shipments to end-users. ArthroCare was DiscoCare’s only client until it acquired DiscoCare in December 2007.

Although Baker was sentenced to 20 years in prison and Gluk drew a 10-year term, the U.S. Court of Appeals for the 5th Circuit overturned the convictions in January 2016 and ordered new trials. Gluk then pleaded guilty to a single count of conspiracy to commit wire fraud and securities fraud.

Baker’s second trial, which began in late July, ended August 18 when the jury in the U.S. District Court for Western Texas convicted him on 12 of 15 counts, according to court documents. The jury found Baker guilty of one count of wire & securities fraud; seven counts of wire fraud; two counts of securities fraud; and two counts of false statements. Baker was found not guilty on two of the wire fraud counts and one count of the false statement charges, according to the documents.

Baker moved to have the wire fraud charges tossed based on the Supreme Court case Honeycutt v. United States, which states that to “obtain property” from a victim, a defendant must personally acquire the property, according to court documents. His motion claimed that “there is no plausible sense” through which he obtained property from ArthoCare’s investors and argued that the government used the wire fraud charges to double-dip what it calls a securities fraud case.

Judge Sam Sparks disagreed, finding that the jury heard ample evidence of Baker’s guilt on the wire fraud charges, citing witness testimony from Gluk and two other co-conspirators that he “directed a scheme to mislead ArthroCare’s investors about the financial condition of the company to inflate the value of ArthroCare’s shares. In executing this scheme, Baker and his co-conspirators manipulated and misrepresented ArthroCare’s revenue as well as concealed the nature and significance of ArthroCare’ s relationship with its distributors and with DiscoCare.”

“In addition, the evidence at trial showed Baker did more than simply direct his colleagues to manipulate revenue. A reasonable juror could have found Baker repeatedly and intentionally lied to investors about ArthroCare’s earnings and revenues through inaccurate public filings, conference calls with investors and direct email. Likewise, a rational trier of fact could have found Baker knew the revenue and earnings he reported were false because he led and participated in efforts to inflate these numbers,” Sparks wrote.

Furthermore, the judge wrote, “a reasonable juror could have concluded Baker lied about the nature of ArthroCare’s relationship with DiscoCare and his role in using DiscoCare to manipulate ArthroCare’s earnings and revenues” during a deposition before the U.S. Securities & Exchange Commission.

“Similarly, a reasonable juror could have concluded Baker lied when he stated the price ArthroCare paid to acquire DiscoCare, $25 million, was not related to the $25 million termination fee in ArthroCare’s contract with DiscoCare,” he wrote.

“In sum, the Court finds the evidence was overwhelming such that a rational jury could conclude beyond a reasonable doubt Baker willfully participated in a conspiracy to commit wire fraud and securities fraud, committed both wire fraud and securities fraud, and made false, material statements to the SEC he knew to be false. Therefore, Baker’s argument the government’s evidence was insufficient to prove guilt beyond a doubt is without merit,” Sparks wrote.

As for the Honeycutt-based argument, Sparks found that “in a scheme to defraud the focus is on depriving a victim of property for some benefit; precedent imposes no requirement that a defendant must directly gain or possess said property.”

“At trial, substantial evidence was presented to show the misleading and fraudulent statements made by Baker induced investment in ArthroCare. Baker’s co-conspirators testified the purpose of the scheme was to attract investment through inflated earnings per share. Testimony also suggested the scheme was intended to enrich Baker and his co-conspirators through bonuses and the appreciation of their own ArthroCare stock and stock options. In particular, evidence produced at trial showed Baker significantly benefitted from the scheme as he received high compensation, collected performance bonuses, and profited from the sale of his personal stock in ArthroCare,” he wrote.

“Additionally, various analysts and investors testified they would not have invested in or recommended investing in ArthroCare if they had known the true state ofArthroCare’s earnings and its relationship with DiscoCare. These same analysts and investors further testified they lost millions of dollars because of Baker’s scheme. Thus, viewing the evidence in the light most favorable to the prosecution, the court concludes a rational trier of fact could have found the goal of the scheme conducted by Baker and his co-conspirators was to deprive investors of money they otherwise would have possessed,” Sparks wrote.

ArthroCare, which was acquired for $1.7 billion by Smith & Nephew (NYSE:SNN) in May 2014, agreed in January 2014 to pay a $30 million fine and enter a deferred prosecution deal to settle its part in the fraud.

Filed Under: Legal News, Wall Street Beat Tagged With: ArthroCare Corp.

In case you missed it

  • CeQur raises $115M for wearable insulin delivery device
  • Survey shows solid medical device industry performance despite pandemic
  • Cardinal Health wins $58M federal PPE contract
  • SentiAR closes $5.1M Series A
  • Endologix acquires PQ Bypass
  • Could BrainCheck’s simple test help COVID long-haulers?
  • Feds halt J&J COVID-19 vaccine due to blood clot concern
  • BioCorp, Roche launch Mallya smart insulin pen in France
  • The top 5 pharma firms by reputation
  • Famed marathoner uses Abbott glucose sensor for training
  • Medical device companies put $3.6 billion in docs’ pockets, study finds
  • DiaSorin to buy Luminex for $1.8B
  • Genentech wins FDA approval for Xolair prefilled syringe
  • FDA slaps Class I label on rapid infuser recall
  • Microsoft spending $19.7B on Nuance and its AI for healthcare providers
  • Memic raises $96M to support surgical robot with humanoid-shaped arm
  • Heater-Cooler suit against LivaNova revived

RSS From Medical Design & Outsourcing

  • Micro to add plant in Costa Rica
    Contract manufacturer Micro today announced plans to open a new plant in Costa Rica. The 32,000 ft² facility will significantly increase Micro’s cleanroom assembly capacity, according to the Somerset, N.J.-based company. It will be located in the Zona Franca Metro business park and is expected to open in late 2021 with operations beginning in 2022.… […]
  • Survey shows solid medical device industry performance despite pandemic
    By Stewart Eisenhart, Emergo Group Medical device and IVD manufacturers report healthy performance over the course of 2020, but also faced significant operational and regulatory challenges related to the coronavirus pandemic. Get the full story here at the Emergo Group’s blog. The opinions expressed in this blog post are the author’s only and do not… […]
  • Cardinal Health wins $58M federal PPE contract
    Cardinal Health (NYSE: CAH) today said it has won a $57.8 million contract from the U.S. Dept. of Health and Human Services to support the Strategic National Stockpile. The Dublin, Ohio-based company received the contract, which includes options that if exercised by the HHS could reach $91.6 million, to store and distribute 80,000 pallets of… […]
  • Qosina adds single-use bioprocessing devices
    Qosina this week launched its product line for the single-use bioprocess industry. The new product line includes tube-to-tube bard connectors, luer fittings, check valves, tubing pinch clamps, tubing, steam thru connectors and more. Get the full story on our sister site, Medical Tubing + Extrusion. The post Qosina adds single-use bioprocessing devices appeared first on […]
  • Could BrainCheck’s simple test help COVID long-haulers?
    BrainCheck‘s eponymous mobile neurocognitive test can detect dementia and concussion. But it has a new application: post-COVID brain fog. Developed by neurologists at Baylor College of Medicine’s Eagleman Laboratory for Perception and Action, BrainCheck carries an FDA Class II Software as a Medical Device (SaMD) designation and can be used on a tablet or laptop… […]
  • XL Precision Technologies holding an April 28 webinar about laser tech
    XL Precision Technologies is holding an online webinar on April 28 at 8 a.m. Eastern time (1 p.m. U.K. time) about laser technology in medical device manufacturing. Register for the webinar here: https://bit.ly/XL-MER-Webinar2 Stockton-on-Tees, U.K.–based XL Precision Technologies provides laser welding, laser cutting of fine tubes and flat material and laser etching of components. It’s… […]
  • Medical device companies put $3.6 billion in docs’ pockets, study finds
    Medtech companies paid $3.62 billion for access to physicians — 10% more than drug companies did — from 2014 to 2017, according to new research. Device company payments to surgical specialists were significantly more tied to the surgeons’ Medicare billing than payments from drug companies to specialists, according to the study, which appears in the… […]
  • FDA slaps Class I label on rapid infuser recall
    The FDA today declared that the recall of an emergency infusion device kit is the most serious type. The recall covers three models of disposable sets made by Smisson-Cartledge Biomedical for its ThermaCor 1200 rapid infuser, which is used for fluid or bolus delivery. The system is made of a footswitch for hands-free fluid control,… […]
  • Cretex breaks ground on new plant north of Minneapolis
    Cretex Cos. last week broke ground on a new 245,000 ft2 medical device contract manufacturing plant in Brooklyn Park, Minn. Elk River, Minn.–based Cretex plans to complete facility construction by the end of the year. The company expects the facility by the end of 2022 to house its stamping, molding and tool design — and… […]
  • Resonetics to expand manufacturing in Costa Rica
    Resonetics announced today it has leased new manufacturing space in Costa Rica to more than double its production there. The space, in a building near its current site in the Coyol Free Zone business park in Alajuela, will be expanded and reconfigured to create a 45,000 ft² production site. The move comes after the company… […]
  • Are Black patients not getting LVADs as quickly as white patients?
    Researchers from the University of Missouri conducted a study that found disparities in treating Black and white patients with advanced heart failure. According to a news release, the study found that Black patients with advanced heart failure were more likely to receive a left ventricular assist device (LVAD) — a pump implanted into the chest… […]

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS